Michael Birrer, MD, PhD, Harvard Medical School, discusses the importance of personalized care for ovarian cancer.
Michael Birrer, MD, PhD, Harvard Medical School, discusses the importance of personalized care for ovarian cancer.
Birrer was involved in conducting a large study that examined elements at diagnosis, such as tumor biomarkers and quality of life, and determining if they can predict why some women with ovarian cancer live longer than others.
This research is important, Birrer says, because it can help personalize care, thus resulting in better survival outcomes and quality of life, and reducing toxicities. As of right now, patients with ovarian cancer, though they fall on a broad spectrum of survival, are treated with a “one size fits all” approach.
FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers
March 22nd 2024Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.